Novel Therapeutic Options for Small Cell Lung Cancer
© 2023. The Author(s)..
PURPOSE OF REVIEW: The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers.
RECENT FINDINGS: In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
Current oncology reports - 25(2023), 11 vom: 23. Nov., Seite 1277-1294 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Canova, Stefania [VerfasserIn] |
---|
Links: |
---|
Themen: |
Immunotherapy |
---|
Anmerkungen: |
Date Completed 13.11.2023 Date Revised 24.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s11912-023-01465-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM363630023 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM363630023 | ||
003 | DE-627 | ||
005 | 20231226093749.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11912-023-01465-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1212.xml |
035 | |a (DE-627)NLM363630023 | ||
035 | |a (NLM)37870696 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Canova, Stefania |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel Therapeutic Options for Small Cell Lung Cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 13.11.2023 | ||
500 | |a Date Revised 24.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a PURPOSE OF REVIEW: The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers | ||
520 | |a RECENT FINDINGS: In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a PARP inhibitors | |
650 | 4 | |a SCLC classification | |
650 | 4 | |a Target therapy | |
700 | 1 | |a Trevisan, Benedetta |e verfasserin |4 aut | |
700 | 1 | |a Abbate, Maria Ida |e verfasserin |4 aut | |
700 | 1 | |a Colonese, Francesca |e verfasserin |4 aut | |
700 | 1 | |a Sala, Luca |e verfasserin |4 aut | |
700 | 1 | |a Baggi, Alice |e verfasserin |4 aut | |
700 | 1 | |a Bianchi, Sofia Paola |e verfasserin |4 aut | |
700 | 1 | |a D'Agostino, Anna |e verfasserin |4 aut | |
700 | 1 | |a Cortinovis, Diego Luigi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d 1999 |g 25(2023), 11 vom: 23. Nov., Seite 1277-1294 |w (DE-627)NLM110371534 |x 1534-6269 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2023 |g number:11 |g day:23 |g month:11 |g pages:1277-1294 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11912-023-01465-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 25 |j 2023 |e 11 |b 23 |c 11 |h 1277-1294 |